Matthew Patterson

Matt is a biotechnology executive with nearly 30 years of experience in the research, development, and commercialization of innovative therapeutics and has held positions of senior management in both private and public biotechnology companies. He is currently serving in the role of Strategic Advisor to Audentes Therapeutics after co-founding and leading the company from 2013 until its sale to Astellas in 2020. Prior to Audentes, Matt was an Entrepreneur-In-Residence with OrbiMed and held senior roles at Amicus Therapeutics, BioMarin Pharmaceutical. and Genzyme Corporation. He serves on several boards, including Homology Medicines, Inc., Vor Biopharma, Inc., 5:01 Acquisition Corporation, and the Alliance for Regenerative Medicine (ARM).